Cargando…

Correction: Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial

Detalles Bibliográficos
Autores principales:	Thompson, Fiona M., Porter, David W., Okitsu, Shinji L., Westerfeld, Nicole, Vogel, Denise, Todryk, Stephen, Poulton, Ian, Correa, Simon, Hutchings, Claire, Berthoud, Tamara, Dunachie, Susanna, Andrews, Laura, Williams, Jack L., Sinden, Robert, Gilbert, Sarah C., Pluschke, Gerd, Zurbriggen, Rinaldo, Hill, Adrian V. S.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072424/ http://dx.doi.org/10.1371/annotation/419b2f36-d46f-4f8a-8ffb-7fd2bfb33aa6

Ejemplares similares

Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial
por: Thompson, Fiona M., et al.
Publicado: (2008)

A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers
por: Genton, Blaise, et al.
Publicado: (2007)

A Virosomal Malaria Peptide Vaccine Elicits a Long-Lasting Sporozoite-Inhibitory Antibody Response in a Phase 1a Clinical Trial
por: Okitsu, Shinji L., et al.
Publicado: (2007)

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations
por: Tamborrini, Marco, et al.
Publicado: (2011)

Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine
por: Tamborrini, Marco, et al.
Publicado: (2009)

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine
por: Porter, David W., et al.
Publicado: (2011)

Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children
por: Cech, Patrick Georges, et al.
Publicado: (2011)

MIG (CXCL9) is a more sensitive measure than IFN-γ of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines
por: Berthoud, Tamara K., et al.
Publicado: (2009)

Corrigendum to “MIG (CXCL9) is a more sensitive measure than IFN-γ of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines” [J. Immunol. Methods 340 (2009) 33–41]
por: Berthoud, Tamara K., et al.
Publicado: (2011)

Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models
por: Tamborrini, Marco, et al.
Publicado: (2020)

Virosome: An engineered virus for vaccine delivery
por: Ali, Hasan, et al.
Publicado: (2023)

Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate
por: Fernandes, Bárbara, et al.
Publicado: (2022)

Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model
por: Dunachie, Susanna, et al.
Publicado: (2015)

P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)

Virosome Presents Multimodel Cancer Therapy without Viral Replication
por: Saga, Kotaro, et al.
Publicado: (2013)

MIG and the Regulatory Cytokines IL-10 and TGF-β1 Correlate with Malaria Vaccine Immunogenicity and Efficacy
por: Dunachie, Susanna J., et al.
Publicado: (2010)

Reconstruction of H(3)N(2) influenza virus based virosome in-vitro
por: Abdoli, Asghar, et al.
Publicado: (2013)

Immunological profile of mice immunized with a polyvalent virosome-based influenza vaccine
por: Fonseca, Francisco Noé, et al.
Publicado: (2023)

Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine
por: Alicino, Cristiano, et al.
Publicado: (2014)

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine
por: Cox, Freek, et al.
Publicado: (2015)

Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein
por: Gargett, Tessa, et al.
Publicado: (2014)

Development, Biological Characterization, and Immunological Evaluation of Virosome Vaccine against Newcastle Disease in Pakistan
por: Rasool, Muhammad Hidayat, et al.
Publicado: (2021)

A polyvalent virosomal influenza vaccine induces broad cellular and humoral immunity in pigs
por: Haach, Vanessa, et al.
Publicado: (2023)

Construction of influenza virosome from influenza A H1N1 PR8
por: Noori, Mehri, et al.
Publicado: (2011)

Influenza T-cell Epitope-Loaded Virosomes Adjuvanted with CpG as a Potential Influenza Vaccine
por: Soema, Peter C., et al.
Publicado: (2014)

Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review
por: Asadi, Khatereh, et al.
Publicado: (2021)

Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice
por: Kamphuis, Tobias, et al.
Publicado: (2012)

A Triple Co-Culture Model of the Human Respiratory Tract to Study Immune-Modulatory Effects of Liposomes and Virosomes
por: Blom, Rebecca A. M., et al.
Publicado: (2016)

Erythro–Magneto–HA–Virosome: A Bio-Inspired Drug Delivery System for Active Targeting of Drugs in the Lungs
por: Vizzoca, Alessio, et al.
Publicado: (2022)

Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability
por: Lederhofer, J., et al.
Publicado: (2018)

Preparation and characterization of nanocurcumin based hybrid virosomes as a drug delivery vehicle with enhanced anticancerous activity and reduced toxicity
por: Kumar, Varun, et al.
Publicado: (2021)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Evaluation of the Sublingual Route for Administration of Influenza H5N1 Virosomes in Combination with the Bacterial Second Messenger c-di-GMP
por: Pedersen, Gabriel Kristian, et al.
Publicado: (2011)

Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice
por: Ebensen, Thomas, et al.
Publicado: (2017)

Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4(+) T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen
por: Blom, Rebecca A. M., et al.
Publicado: (2017)

Virosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy
por: Liu, Qiushi, et al.
Publicado: (2015)

Matrix‐M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model
por: Pedersen, Gabriel, et al.
Publicado: (2011)

New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes
por: Amacker, Mario, et al.
Publicado: (2020)

A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
por: van der Velden, Yme U., et al.
Publicado: (2022)

Differential Gene Repertoire in Mycobacterium ulcerans Identifies Candidate Genes for Patho-Adaptation
por: Käser, Michael, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_e0q96c0tcrsla1ph0r3m30ddtr